Global Scans · Pharmaceuticals · Weekly Summary

• [New] Leading Drug Therapy: Antipsychotic drugs are projected to dominate due to their established clinical efficacy, widespread adoption, and functional integration across pediatric and adolescent care settings, holding approximately 42% share in 2026. Persistence Market Research
• [New] Without urgent action, the WHO warns, drug-resistant infections could claim 39 million lives worldwide by 2050 and impose an annual economic burden of up to $412bn (£307bn). The Guardian
• [New] The approaching patent cliff-projected to expose as much as $300 billion in annual drug sales to loss of exclusivity by 2032 - is expected to keep pharmaceutical M&A activity active in 2026, but not necessarily drive a dramatic year-over-year spike in deal volume or size. Pharmaceutical Commerce
• [New] Investigational New Drug - enabling studies are expected to begin in H1 2026. GlobeNewswire
• [New] The latest change could cut $20 million from the cost of developing a biosimilar drug, potentially lowering the end price for consumers. American Chemical Society
• [New] The Patent Cliff: Between 2026 and 2030, Pfizer will lose exclusivity on drugs representing roughly $17 billion in annual revenue, including the blockbuster blood thinner Eliquis and the cancer drug Ibrance. The Chronicle-Journal
• [New] Long-term value: McKinsey estimates potential economic value from quantum computing applications in life sciences and drug discovery alone of $200 billion to $500 billion by 2035. Trantorinc
• [New] More individuals are enrolled in Medicare Advantage plans offering drug coverage compared to stand-alone prescription drug plans. ElderVoice
• [New] The global pharmaceutical industry is projected to surpass $1.8 trillion by 2026, driven by innovation, ageing populations, and expanding healthcare access. LinkedIn
• Diet changes linked to GLP-1 drug use could reach upwards of $12 billion snack sales lost over the next decade. FoodNavigator-USA.com
• Premium pharmaceutical-grade fish oil with high EPA and DHA concentration is expected to witness robust demand growth. openpr
• Sweden's nationwide PGx implementation could prevent adverse drug events annually. Market Data Forecast

Last updated: 17 March 2026